Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic, and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.
Abstract
Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from a somatic cell. The iPSC technology was pioneered by Shinya Yamanaka’s lab in Kyoto, Japan, who showed in 2006 that the introduction of four specific genes (named Myc, Oct3/4, Sox2 and Klf4) encoding transcription factors could convert somatic cells into pluripotent stem cells. He was awarded the 2012 Nobel Prize along with Sir John Gurdon "for the discovery that mature cells can be reprogrammed to become pluripotent."
Pluripotent stem cells hold promise in the field of regenerative medicine. Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic, and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.
Recognising the central role of VSELs/progenitors and their niche in maintaining tissue homeostasis in vivo could resolve existing roadblocks and guide more effective endogenous regenerative therapies for diseased tissues and age-related dysfunctions.
D. Bhartiya, N. Sharma, Anish Tripathi et al.· Stem Cell Reviews and Report...· 0 citations
Key applications of iPSC technology in hemato-oncology are summarized, its major advantages and current limitations are discussed, and emerging directions are highlighted, including scalable iPSC-derived blood cell therapies for inherited and acquired bone marrow failure syndromes and leukemia.
Ivan Tesakov, M. Nasri, M. Klimiankou et al.· Frontiers in Immunology· 0 citations
Simple Summary Human in vitro gametogenesis is the focus of researchers, as pluripotent stem cell derived human primordial germ cell-like cells (hPGCLCs) could not complete the meiotic division. Therefore, generating early hPGCLCs, which provides an opportunity for further investigations to overcome a meiotic block, is a cue of success in deriving haploid gametes in vitro. Thus, we described a protocol for hPGCLC specification of human pluripotent stem cells (hPSCs) through sequential induction with Activin A for 2 days and BMP4 for 6 days in 2D and 3D culture systems. Induction of hPSCs into hPGCLCs demonstrated expression of early primordial germ cell markers, including PRDM1, NANOS3, DAZL, STELLA, SOX17, SSEA1, and cKIT, on the 8th day of hPGCLC generation.
V. K. Abdyev, P.I. Sirotkina, E. D. Erofeeva et al.· Biology· 0 citations
This review summarizes research with a focus on clinical translation of iPSC-derived immune cells, as well as highlights continued challenges and prospects of this field.
Luisjesus S. Cruz, Alejandro R. Castañeda, Dan S. Kaufman· Stem Cells· 0 citations
This Review evaluates the technological and translational trajectories that have defined the iPSC era and analyzes the operational barriers to therapeutic development, envisioning a paradigm shift in which iPSC-derived interventions transition from bespoke experimental models toward standardized, engineered biological medicines.
Jaecheol Lee, Todd J. Herron, Lorenz Studer et al.· Nature Medicine· 0 citations
This platform enables mechanistic studies of thymic stromal dysfunction and advances understanding of immune deficits in these disorders and reveals disease-specific mesenchymal defects underlying thymic abnormalities in congenital syndromes.
Giuseppe Sangiorgio, Francesca Pala, Kayla Amini et al.· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
